Based on the Phase 1 results and preclinical profile of VG-3927, the Company plans to advance a once-daily oral dose of 25mg that fully engages the desired pharmacology and expects to initiate the ...
A study led by Turkish researcher Pinar Ayata unveiled a critical mechanism involving microglia—specialized immune cells in the brain—that could open new avenues for treating Alzheimer's ...
The study highlights microglia, the brain's primary immune cells, as central players in both the protective and harmful responses associated with the disease. Researchers with the Advanced Science ...
Electron micrographs show typical microglia in the prefrontal cortex of a 92-year-old healthy female (left) and dark microglia a 91-year-old female patient with Alzheimer’s disease (right).
American researchers say it marks a "promising" target for drug treatments aiming to slow, or even reverse, the disease's development ... immune cells - called microglia - play a key role in ...